Lineage, Inc. Common Stock (LINE)vsUBS Group AG (UBS)
LINE
Lineage, Inc. Common Stock
$39.96
-0.03%
REAL ESTATE · Cap: $10.02B
UBS
UBS Group AG
$45.23
+1.85%
FINANCIAL SERVICES · Cap: $148.26B
Smart Verdict
WallStSmart Research — data-driven comparison
UBS Group AG generates 857% more annual revenue ($51.31B vs $5.36B). UBS leads profitability with a 17.8% profit margin vs -2.7%. UBS earns a higher WallStSmart Score of 79/100 (B+).
LINE
Hold39
out of 100
Grade: F
UBS
Strong Buy79
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+75.9%
Fair Value
$161.27
Current Price
$39.96
$121.31 discount
Intrinsic value data unavailable for UBS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 31.5%
Earnings expanding 84.4% YoY
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.4% revenue growth
0.0% earnings growth
Operating margin of 3.3%
ROE of -1.8% — below average capital efficiency
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : UBS
The strongest argument for UBS centers on Operating Margin, EPS Growth, Market Cap. Profitability is solid with margins at 17.8% and operating margin at 31.5%. Revenue growth of 13.8% demonstrates continued momentum.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : UBS
No major red flags identified for UBS, but monitor valuation.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while UBS is a mature play — different risk/reward profiles.
UBS is growing revenue faster at 13.8% — sustainability is the question.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
UBS scores higher overall (79/100 vs 39/100), backed by strong 17.8% margins and 13.8% revenue growth. LINE offers better value entry with a 75.9% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm focused on regenerative medicine, specifically developing cutting-edge cell therapy solutions for treating debilitating conditions, including ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust network of strategic collaborations, Lineage is poised to transform patient care through innovative therapeutic interventions. The company's commitment to advancing its diverse product pipeline and expediting clinical research positions it as an attractive investment opportunity for institutional investors seeking to engage in the forefront of healthcare advancements.
Visit Website →UBS Group AG
FINANCIAL SERVICES · BANKS - DIVERSIFIED · USA
UBS Group AG, provides advice and financial solutions to private, institutional and corporate clients worldwide. The company is headquartered in Zurich, Switzerland.
Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?